On January 10, 2025, OIG posted a favorable advisory opinion approving a proposed program (Program) to provide patients who meet certain financial need criteria with free access to a pharmaceutical product that has limited...more
1/28/2025
/ Anti-Kickback Statute ,
Compliance ,
Drug Pricing ,
Federal Health Care Programs (FHCP) ,
Healthcare Fraud ,
Incentives ,
Medicaid ,
Medicare ,
OIG ,
Pharmaceutical Industry ,
Prescription Drugs ,
Reimbursements